Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 10/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349399 | 0.91 | PAK1 (0.45) | PAK1HPGDSGRIN2B | |
| SCHEMBL5658584 | 0.87 | PAK1 (0.46) | PAK1HPGDSGRIN2B | |
| SCHEMBL8271780 | 0.87 | HPGDS (0.43) | PAK1HPGDSGRIN2B | |
| SCHEMBL8271772 | 0.87 | HPGDS (0.43) | PAK1HPGDSGRIN2B | |
| SCHEMBL14349445 | 0.87 | PAK1 (0.45) | PAK1HPGDSGRIN2B | |
| SCHEMBL18331855 | 0.87 | HPGDS (0.43) | PAK1HPGDSGRIN2B | |
| SCHEMBL5660340 | 0.87 | LMNA (0.45) | PAK1HPGDSGRIN2BMAPK1 | |
| SCHEMBL8271774 | 0.86 | HPGDS (0.41) | PAK1HPGDSGRIN2B | |
| SCHEMBL14349427 | 0.86 | GRIN2B (0.40) | PAK1HPGDSGRIN2B | |
| SCHEMBL8271778 | 0.86 | MAPK1 (0.43) | PAK1HPGDSGRIN2BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| WO-2006017409-A2 | 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293515-A1 | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists | GRIN2B, GRIN2A, GRIN1 | PAK1 2143/4885HPGDS 1733/4885GRIN2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.